klow protocol peptide dosage Codex Klow Peptide Dosage: Complete Protocol

10.1155/2021/9929687 50 ZhaoX.YangF.WuH.FanZ.WeiG.ZouY.et al (2024)

The Cardiac Arrhythmia Suppression Trials (CAST I and II) showed that patients with a history of myocardial infarction, treated with class IC agents (flecainide, encainide, moricizine) to reduce premature ventricular contractions (PVCs), faced a higher mortality risk compared to those receiving a placebo (72)

Interest in such applications is largely driven by their proposed mechanisms of action, including enhancement of tissue repair, modulation of inflammation, and cytoprotective effects observed in preclinical studies

The treatment should be pulsed rather than continuous

FDA's 2013 determination states those products weren't withdrawn for safety or effectiveness reasons - it doesn't state why the manufacturer discontinued them